BMS makes $4.5 billion bid for ImClone Systems
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibbhas made a $4.5 billion cash offer to acquire ImClone Systems– a move which would consolidate the firms' six year relationship. The $60 per share offer represents a 30% premium on ImClone's closing price yesterday.